Every 8-K that AVAI BIO INC (AVAI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow AVAI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVAI filings page.
Avai Bio, Inc. entered into a Mutual Termination Agreement with Ainnova Tech Inc. on May 7, 2026, ending their Joint Venture and License Agreement that began in November 2024. The joint venture entity, Ai-Nova Acquisition Corp., will be dissolved and its Nevada corporate filings closed.
Both parties agreed to cancel and release all obligations, rights, and liabilities related to the prior arrangement, with no termination penalties or further financial obligations for either side. Avai Bio and Ainnova plan to pursue their business strategies independently while cooperating in good faith to wind down any remaining joint venture activities.
AVAI Bio, Inc., formerly Avant Technologies, Inc., reported a corporate name change. On February 3, 2026, the Nevada corporation filed a Certificate of Amendment to its Articles of Incorporation with the Nevada Secretary of State to change its name to Avaí Bio, Inc. The company’s ticker symbol will remain “AVAI.”
Avant Technologies Inc. (AVAI) entered a Joint Venture and License Agreement with SGAustria Pte. Ltd. to form Insulinova, Inc. Effective November 1, 2025, the parties will co-own Insulinova on a 50%/50% basis and operate it under a limited liability company agreement.
Austrianova intends to contribute its proprietary cell encapsulation intellectual property, know-how, and related resources. AVAI will contribute all resources and capital required for the first eighteen months, not to exceed $1.5 million USD, in exchange for Insulinova common stock, and will use its best efforts to help arrange additional funding at no cost to Austrianova. The full agreement is attached as Exhibit 10.1.
Avant Technologies Inc. entered into a Joint Venture and License Agreement with SGAustria Pte. Ltd. (Austrianova) to form a new company, Klothonova Inc. Avant will provide all resources and capital needed for Klothonova’s formation and operations for the next 18 months, up to $1.5 million, in exchange for common stock.
Austrianova, a biotech company specializing in cell biology and proprietary cell encapsulation technology, will contribute its intellectual property, know-how, and resources. Ownership of Klothonova will be split 50% to Avant and 50% to Austrianova, and it will be governed under a limited liability company agreement. The full Joint Venture and License Agreement is attached as Exhibit 10.1.
Avant Technologies Inc. reported that it has filed an application with FINRA to change its corporate name. The company plans to change its name from Avant Technologies Inc. to Avaí Bio, Inc. to better reflect its current business. The ticker symbol will remain “AVAI” until FINRA declares the corporate action effective and, if applicable, assigns a new trading symbol.